InvestorsHub Logo
icon url

HazerOutlaw

10/16/20 6:30 PM

#319001 RE: rogers5729 #318916

Agree that there's nothing to be read into re: 10 mins for the LBA. They are routinely 10-15 minute sessions; start, show the data, entertain a couple of questions, and that's it.

But the LBA selection process, and the idea that it's not likely to be a let-down because it's selected for an LBA... Just a little bit of caution around this thinking. I've attended many, many late-breakers in which the outcome of the study showed a lack of effect or benefit for a drug being studied. LBAs are chosen by the societies holding these meetings based on the information being presented — meaning, the importance of this information to clinicians in practice, and the likelihood that the results discussed will impact physician behavior and patient care in the real world. Positive or negative.

However, one can easily imagine that SNO is looking at the potential impact of a positive outcome for DCVax, and basing their selection of this session as an LBA based on that potential.

As for Stupp being on the follow-up roundtable - nice catch there. Interesting!